Pfizer is launching seven phase 3 studies for PF-4044 soon and plans to initiate an additional 10 (at least) by the end of ...

Over the past two decades, thoracic oncology has undergone a profound transformation, moving from limited chemotherapy ...

Arvinas stock has seen its fair value estimate hold steady at $12.31 per share, even as the discount rate decreased slightly to 6.96%. This stability comes as analysts weigh varying perspectives on ...

The treatment strategy may involve a combination of surgery, radiation therapy, immunotherapy, and chemotherapy, each aimed at slowing disease progression and, in many cases, temporarily reducing the ...

Flatiron Health today announced its presence at the San Antonio Breast Cancer Symposium (SABCS) happening from December 9-12, 2025, in San Antonio, Texas. Flatiron's real-world data and research ...

Pfizer's concerted effort to move beyond its pandemic-era business and establish a new growth foundation in oncology faced an unexpected challenge this week. A revelation concerning regulatory ...

Next-Generation Biologics and Biosimilars Market to Hit 251.13 billion Dollars by 2033 - Strategic Revenue Insights (SRI) ...

Pillar Biosciences, the leader in Decision Medicinetm, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized its pricing determination for oncoReveal CDx. Following its ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology ...

Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer Screening Platform Vancouver, British Columbia–(Newsfile Corp. – December ...

British drugmaker AstraZeneca ($AZN), fresh off a record-high stock price, continues to draw interest from U.S. and European ...

Shares of BioNTech, the German vaccine innovator, came under significant pressure on a pivotal Tuesday. The sell-off, which ...